86.53
0.37%
0.32
After Hours:
86.53
Vaxcyte Inc stock is traded at $86.53, with a volume of 3.43M.
It is up +0.37% in the last 24 hours and up +0.66% over the past month.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
See More
Previous Close:
$86.21
Open:
$86.45
24h Volume:
3.43M
Relative Volume:
3.30
Market Cap:
$10.78B
Revenue:
-
Net Income/Loss:
$-507.65M
P/E Ratio:
-22.32
EPS:
-3.876
Net Cash Flow:
$-616.24M
1W Performance:
-1.36%
1M Performance:
+0.66%
6M Performance:
+18.93%
1Y Performance:
+45.36%
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
86.53 | 10.78B | 0 | -507.65M | -616.24M | -4.60 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-07-23 | Initiated | Mizuho | Buy |
Apr-18-23 | Initiated | TD Cowen | Outperform |
Jan-03-23 | Reiterated | Needham | Buy |
Dec-15-22 | Initiated | Guggenheim | Buy |
Nov-17-22 | Initiated | BTIG Research | Buy |
Dec-29-21 | Resumed | Jefferies | Buy |
Jun-24-21 | Resumed | Jefferies | Buy |
Jul-07-20 | Initiated | BofA Securities | Buy |
Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Vaxcyte a new buy at Goldman Sachs on vaccine platform, pneumonia asset - MSN
Vaxcyte a new buy at Goldman Sachs on vaccine platform, pneumonia asset (PCVX:NASDAQ) - Seeking Alpha
The Goldman Sachs Group Begins Coverage on Vaxcyte (NASDAQ:PCVX) - MarketBeat
Vaxcyte stock supported by Goldman Sachs for addressing next-gen vaccine challenges - Investing.com
Vaxcyte's president and CFO sells $710,248 in stock transactions - Investing.com India
Vaxcyte's president and CFO sells $710,248 in stock transactions By Investing.com - Investing.com Canada
Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells 8,000 Shares of Stock - MarketBeat
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm - EIN News
(PCVX) Investment Report - Stock Traders Daily
Lord Abbett & CO. LLC Raises Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Franklin Resources Inc. Raises Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Geode Capital Management LLC Buys 259,010 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Receives $147.50 Average Price Target from Analysts - MarketBeat
Applied Industrial Technologies (AIT-N) QuotePress Release - The Globe and Mail
Merck & Company (MRK-N) QuotePress Release - The Globe and Mail
Why Wall Street Rates These 2 Russell 2000 Stocks a “Strong Buy” - MSN
Pfizer Inc (PFE-N) QuotePress Release - The Globe and Mail
Alexandria Real Estate Equities, Inc. Announces Long-Term 258,581 RSF Lease With Longstanding Tenant Vaxcyte, Inc. at the Alexandria Center for Life ScienceSan Carlos Mega Campus (PR Newswire) - Aktiellt
Vaxcyte, Inc. (NASDAQ:PCVX) is Frazier Life Sciences Management L.P.'s 7th Largest Position - MarketBeat
Y Intercept Hong Kong Ltd Increases Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Zacks Investment Management Acquires Shares of 13,645 Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
State Street Corp Increases Position in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
What Makes Vaxcyte (PCVX) An Investment Bet? - MSN
Vaxcyte's SVP Mikhail Eydelman sells $457k in stock By Investing.com - Investing.com UK
Stocks With Rising Relative Strength: Vaxcyte - MSN
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely - Simply Wall St
Pier Capital LLC Reduces Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
(PCVX) Trading Signals - Stock Traders Daily
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by RA Capital Management L.P. - MarketBeat
Point72 Asset Management L.P. Takes Position in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Polar Asset Management Partners Inc. Sells 44,200 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Bank of Montreal Can Invests $3.10 Million in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte doses first subject in pneumococcal conjugate vaccine trial in infants - Yahoo! Voices
Parkman Healthcare Partners LLC Trims Stake in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Maven Securities LTD Acquires Shares of 129,700 Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Bamco Inc. NY Makes New $3.54 Million Investment in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Vaxcyte CEO Grant Pickering sells $1.39 million in stock By Investing.com - Investing.com Canada
Vaxcyte CEO Grant Pickering sells $1.39 million in stock - Investing.com
Vaxcyte COO Jim Wassil sells $739,884 in stock By Investing.com - Investing.com UK
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants - GlobeNewswire
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal - The Bakersfield Californian
HighVista Strategies LLC Grows Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Cinctive Capital Management LP Purchases Shares of 32,494 Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat
Braidwell LP Sells 510,735 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Fred Alger Management LLC Reduces Stake in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Eventide Asset Management LLC Has $43.82 Million Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaccine maker doubles its space at Bay Area biotech mega-campus - MSN
Acuta Capital Partners LLC Has $15.47 Million Stake in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte (PCVX) Surged On Positive Phase 2 Data For Its Drug - MSN
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vaxcyte Inc Stock (PCVX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
GUGGENHIME ANDREW | PRESIDENT AND CFO |
Dec 18 '24 |
Sale |
88.78 |
8,000 |
710,249 |
109,491 |
Cowan Elvia | SVP, FINANCE |
Dec 16 '24 |
Option Exercise |
25.92 |
7,716 |
199,999 |
19,294 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):